Outcome Disparities among Ethntic Subgroups of Waldenstrom's Macroglobulinemia: A Population-Based Study

被引:19
|
作者
Ailawadhi, Sikander [1 ]
Kardosh, Adel [2 ]
Yang, Dongyun [3 ]
Cozen, Wendy [3 ]
Patel, Gaurav [4 ]
Alamgir, Mohammad A. [2 ]
Chanan-Khan, Asher A. [1 ]
机构
[1] Mayo Clin Jacksonville, Div Hematol & Oncol, Jacksonville, FL 32224 USA
[2] Univ So Calif, Div Hematol, Los Angeles, CA USA
[3] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA
[4] Calif State Univ Northridge, Dept Hlth Sci, Northridge, CA 91330 USA
关键词
Waldenstrom's macroglobulinemia; Surveillance Epidemiology and End Results; Survival; Ethnicity; Disparity; PROGNOSTIC SCORING SYSTEM; MULTIPLE-MYELOMA; UNITED-STATES; SURVIVAL; PATTERNS;
D O I
10.1159/000360992
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ethnic disparities in cancers are associated with variability in clinical outcomes. We present a Surveillance Epidemiology and End Results (SEER)-based outcome analysis of multiethnic Waldenstrom's macroglobulinemia (WM) patients. Methods: Adult WM patients diagnosed in 1992 or later (n = 3,175) were analyzed. Median overall survival (OS) was compared across different ethnicities stratified by year of diagnosis, registry identification, age at diagnosis, sex, and marital status. Results: African-Americans (AA) had the youngest median age at diagnosis (63 years) and Whites had the oldest (73 years) (p < 0.001). Female gender, a younger age at diagnosis, and a recent year of diagnosis were associated with an improved OS. Hispanics had the worst (5.6 years) while Whites had the best (6.8 years) median OS. A significant interaction existed between median OS, gender, and race (p = 0.007). Among males, AA had the worst (4.3 years) and Asians had the best (7.3 years) median OS. A significant interaction was also noted between median OS, age at diagnosis, and race (p = 0.033). The worst median OS was seen in Hispanics among patients aged >75 years, and in AA among those aged <65 years. Conclusions: These disparities among WM patients may be multifactorial but need to be explored systematically to better understand the disease biology and for optimal triaging of health care resources. (C) 2014 S. Karger AG, Basel
引用
收藏
页码:253 / 262
页数:10
相关论文
共 50 条
  • [1] Second primary malignancies in Waldenstrom's macroglobulinemia: a US population-based study
    Giri, Smith
    Pathak, Ranjan
    Aryal, Madan Raj
    Karmacharya, Paras
    Bhatt, Vijaya Raj
    Martin, Mike G.
    [J]. CANCER CAUSES & CONTROL, 2015, 26 (04) : 645 - 647
  • [2] Second primary malignancies in Waldenstrom’s macroglobulinemia: a US population-based study
    Smith Giri
    Ranjan Pathak
    Madan Raj Aryal
    Paras Karmacharya
    Vijaya Raj Bhatt
    Mike G. Martin
    [J]. Cancer Causes & Control, 2015, 26 : 645 - 647
  • [3] Trends in Incidence and Mortality of Waldenstrom Macroglobulinemia: A Population-Based Study
    Yin, Xuejiao
    Chen, Lei
    Fan, Fengjuan
    Yan, Han
    Zhang, Yuyang
    Huang, Zhenli
    Sun, Chunyan
    Hu, Yu
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [4] Outcome Disparities In Waldenstrom's Macroglobulinemia: A SEER Database Analysis
    Ailawadhi, Sikander
    Yang, Dongyun
    Patel, Gaurav
    Zhang, Yin
    Aldoss, Ibrahim T.
    Kim, Miriam Y.
    Chanan-Khan, Asher
    [J]. BLOOD, 2011, 118 (21) : 386 - 386
  • [5] Population-based study on the impact of the familial form of Waldenstrom macroglobulinemia on overall survival
    Steingrimsson, Vilhjalmur
    Lund, Sigrun Helga
    Turesson, Ingemar
    Goldin, Lynn R.
    Bjorkholm, Magnus
    Landgren, Ola
    Kristinsson, Sigurdur Y.
    [J]. BLOOD, 2015, 125 (13) : 2174 - 2175
  • [6] Familial characteristics of Waldenstrom's macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL):: A population-based study in Sweden
    Kristinsson, S. Y.
    Bjorkholm, M.
    Goldin, L. R.
    McMaster, M. L.
    Turesson, I.
    Landgren, O.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 166 - 166
  • [7] Evolution of Management and Outcomes in Waldenstrom Macroglobulinemia: A Population-Based Analysis
    Olszewski, Adam J.
    Treon, Steven P.
    Castillo, Jorge J.
    [J]. ONCOLOGIST, 2016, 21 (11): : 1377 - 1386
  • [8] Trends in Incidence and Mortality of Waldenstrom Macroglobulinemia: A Population-Based Study (vol 10, 1712, 2020)
    Yin, Xuejiao
    Chen, Lei
    Fan, Fengjuan
    Yan, Han
    Zhang, Yuyang
    Huang, Zhenli
    Sun, Chunyan
    Hu, Yu
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] Risk of Second Cancers in Waldenstrom Macroglobulinemia: a Population-Based Study From Northern Italy.
    Varettoni, Marzia
    Tedeschi, Alessandra
    Pascutto, Cristiana
    Vismara, Eleonora
    Arcaini, Luca
    Greco, Antonino
    Orlandi, Ester
    Ricci, Francesca
    Corso, Alessandro
    Miqueleiz, Sara
    Astori, Cesare
    Lazzarino, Mario
    Morra, Enrica
    [J]. BLOOD, 2009, 114 (22) : 1519 - 1519
  • [10] Incidence, prevalence, mortality, and causes of death in Waldenstrom macroglobulinemia: a nationwide, population-based cohort study
    Jeong, Seri
    Kong, Seom Gim
    Kim, Da Jung
    Lee, Sangjin
    Lee, Ho Sup
    [J]. BMC CANCER, 2020, 20 (01)